Figure S2 from The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

Figure S2. Primary tumor incidence and growth in BrafCA;Cdkn2af/f mice is not altered by ARF6-GTP. (a) Primary tumor incidence (% = # of mice that developed a tumor / # TVA positive, injected mice) in control and overlapping Arf6Q67L cohorts. Two Arf6Q67L cohorts, classified according to detectable or undetectable HA-tagged Arf6Q67L expression by qRT-PCR and/or by anti-HA immunohistochemistry (see Figure S1). Cohort A includes all mice injected with RCAS Cre + Arf6Q67L. Cohort B is limited to only those mice from cohort A with detectable Arf6Q67L in tumors. Fisher's exact test, two tailed,a<0.05. b) Primary tumor growth upon tumor onset, bars = SD. (c) Overall survival upon tumor onset, log-rank (Mantel-Cox) test. (d) Metastatic incidence (# mice with metastasis / # mice with primary tumors). (e) Proliferation, BrafCA;Cdkn2af/f mouse melanoma cells. (f). Apoptosis, BrafCA;Cdkn2af/f mouse melanoma cells. (g) Representative images of Ki67 immunostains, 200x magnification, scale bars = 50um.